Demographic and clinical characteristics of the PROSCIS-B cohort
| Characteristic . | CH negative (n = 345) . | CH positive (n = 236) . | Total (n = 581) . | P value∗ . |
|---|---|---|---|---|
| Age, median (IQR), y | 64 (55-73) | 73.5 (66.75-81) | 68 (59-76) | <.001 |
| Sex, no. (%) | .012 | |||
| Female | 227 (65.8) | 130 (55.1) | 357 (61.4) | |
| Male | 118 (34.2) | 106 (44.9) | 224 (38.6) | |
| TOAST classification, no. (%) | .037 | |||
| Large-artery atherosclerosis | 77 (22.3) | 76 (32.2) | 153 (26.3) | |
| Cardiac embolism | 80 (23.2) | 60 (25.4) | 140 (24.1) | |
| Small-artery occlusion | 61 (17.7) | 32 (13.6) | 93 (16.0) | |
| Other determined cause | 12 (3.5) | 4 (1.7) | 16 (2.8) | |
| Undetermined cause | 115 (33.3) | 64 (27.1) | 179 (30.8) | |
| Modified ranking scale, no. (%) | 1 | |||
| ≤1 | 224 (64.9) | 153 (64.8) | 377 (64.9) | |
| ≥2 | 121 (35.1) | 83 (35.2) | 204 (35.1) | |
| NIHSS score, no. (%) | .08 | |||
| ≤4 | 268 (77.7) | 168 (71.2) | 436 (75.0) | |
| >4 | 77 (22.3) | 68 (28.8) | 145 (25.0) | |
| Smoking status, no. (%) | .002 | |||
| Never smoker | 114 (33.4) | 108 (46.8) | 222 (38.8) | |
| Current or former smoker | 227 (66.5) | 123 (53.2) | 350 (61.2) | |
| Arterial hypertension, no. (%) | .01 | |||
| No | 136 (39.4) | 68 (28.8) | 204 (35.1) | |
| Yes | 209 (60.6) | 168 (71.2) | 377 (64.9) | |
| Diabetes mellitus, no. (%) | .066 | |||
| No | 279 (80.9) | 175 (74.2) | 454 (78.1) | |
| Yes | 66 (19.1) | 61 (25.8) | 127 (21.9) | |
| Dyslipidemia, no. (%) | .754 | |||
| No | 272 (79.8) | 183 (78.5) | 455 (79.3) | |
| Yes | 69 (20.2) | 50 (21.5) | 119 (20.7) | |
| Obesity, no. (%) | .022 | |||
| No | 250 (72.7) | 186 (80.9) | 436 (76.0) | |
| Yes | 94 (27.3) | 44 (19.1) | 138 (24.0) | |
| Atrial fibrillation, no. (%) | .01 | |||
| No | 283 (82.0) | 172 (72.9) | 455 (78.3) | |
| Yes | 62 (18.0) | 64 (27.1) | 126 (21.7) | |
| Coronary heart disease, no. (%) | .91 | |||
| No | 287 (83.2) | 198 (83.9) | 485 (83.5) | |
| Yes | 58 (16.8) | 38 (16.1) | 96 (16.5) | |
| Peripheral artery disease, no. (%) | .043 | |||
| No | 328 (95.1) | 214 (90.7) | 542 (93.3) | |
| Yes | 17 (4.9) | 22 (9.3) | 39 (6.7) | |
| History of cancer, no. (%) | .30 | |||
| No | 313 (92.3) | 210 (89.7) | 523 (91.3) | |
| Yes | 26 (7.7) | 24 (10.3) | 50 (8.7) | |
| Statin therapy, no. (%) | .41 | |||
| None | 50 (14.7) | 26 (11.1) | 76 (13.3) | |
| Low dose | 243 (71.7) | 178 (76.1) | 421 (73.5) | |
| High dose† | 46 (13.6) | 30 (12.8) | 76 (13.3) | |
| Antithrombotics, no. (%) | .19 | |||
| None | 0 (0.0) | 1 (0.4) | 1 (0.2) | |
| Antiplatelet | 271 (79.9) | 174 (74.4) | 445 (77.7) | |
| Anticoagulation | 61 (18.0) | 50 (21.4) | 111 (19.4) | |
| Both | 7 (2.1) | 9 (3.8) | 16 (2.8) | |
| IL-6R p.D358A, no. (%) | .069 | |||
| D/D | 148 (42.9) | 91 (38.6) | 239 (41.1) | |
| D/A | 146 (42.3) | 121 (51.3) | 267 (46.0) | |
| A/A | 51 (14.8) | 24 (10.2) | 75 (12.9) |
| Characteristic . | CH negative (n = 345) . | CH positive (n = 236) . | Total (n = 581) . | P value∗ . |
|---|---|---|---|---|
| Age, median (IQR), y | 64 (55-73) | 73.5 (66.75-81) | 68 (59-76) | <.001 |
| Sex, no. (%) | .012 | |||
| Female | 227 (65.8) | 130 (55.1) | 357 (61.4) | |
| Male | 118 (34.2) | 106 (44.9) | 224 (38.6) | |
| TOAST classification, no. (%) | .037 | |||
| Large-artery atherosclerosis | 77 (22.3) | 76 (32.2) | 153 (26.3) | |
| Cardiac embolism | 80 (23.2) | 60 (25.4) | 140 (24.1) | |
| Small-artery occlusion | 61 (17.7) | 32 (13.6) | 93 (16.0) | |
| Other determined cause | 12 (3.5) | 4 (1.7) | 16 (2.8) | |
| Undetermined cause | 115 (33.3) | 64 (27.1) | 179 (30.8) | |
| Modified ranking scale, no. (%) | 1 | |||
| ≤1 | 224 (64.9) | 153 (64.8) | 377 (64.9) | |
| ≥2 | 121 (35.1) | 83 (35.2) | 204 (35.1) | |
| NIHSS score, no. (%) | .08 | |||
| ≤4 | 268 (77.7) | 168 (71.2) | 436 (75.0) | |
| >4 | 77 (22.3) | 68 (28.8) | 145 (25.0) | |
| Smoking status, no. (%) | .002 | |||
| Never smoker | 114 (33.4) | 108 (46.8) | 222 (38.8) | |
| Current or former smoker | 227 (66.5) | 123 (53.2) | 350 (61.2) | |
| Arterial hypertension, no. (%) | .01 | |||
| No | 136 (39.4) | 68 (28.8) | 204 (35.1) | |
| Yes | 209 (60.6) | 168 (71.2) | 377 (64.9) | |
| Diabetes mellitus, no. (%) | .066 | |||
| No | 279 (80.9) | 175 (74.2) | 454 (78.1) | |
| Yes | 66 (19.1) | 61 (25.8) | 127 (21.9) | |
| Dyslipidemia, no. (%) | .754 | |||
| No | 272 (79.8) | 183 (78.5) | 455 (79.3) | |
| Yes | 69 (20.2) | 50 (21.5) | 119 (20.7) | |
| Obesity, no. (%) | .022 | |||
| No | 250 (72.7) | 186 (80.9) | 436 (76.0) | |
| Yes | 94 (27.3) | 44 (19.1) | 138 (24.0) | |
| Atrial fibrillation, no. (%) | .01 | |||
| No | 283 (82.0) | 172 (72.9) | 455 (78.3) | |
| Yes | 62 (18.0) | 64 (27.1) | 126 (21.7) | |
| Coronary heart disease, no. (%) | .91 | |||
| No | 287 (83.2) | 198 (83.9) | 485 (83.5) | |
| Yes | 58 (16.8) | 38 (16.1) | 96 (16.5) | |
| Peripheral artery disease, no. (%) | .043 | |||
| No | 328 (95.1) | 214 (90.7) | 542 (93.3) | |
| Yes | 17 (4.9) | 22 (9.3) | 39 (6.7) | |
| History of cancer, no. (%) | .30 | |||
| No | 313 (92.3) | 210 (89.7) | 523 (91.3) | |
| Yes | 26 (7.7) | 24 (10.3) | 50 (8.7) | |
| Statin therapy, no. (%) | .41 | |||
| None | 50 (14.7) | 26 (11.1) | 76 (13.3) | |
| Low dose | 243 (71.7) | 178 (76.1) | 421 (73.5) | |
| High dose† | 46 (13.6) | 30 (12.8) | 76 (13.3) | |
| Antithrombotics, no. (%) | .19 | |||
| None | 0 (0.0) | 1 (0.4) | 1 (0.2) | |
| Antiplatelet | 271 (79.9) | 174 (74.4) | 445 (77.7) | |
| Anticoagulation | 61 (18.0) | 50 (21.4) | 111 (19.4) | |
| Both | 7 (2.1) | 9 (3.8) | 16 (2.8) | |
| IL-6R p.D358A, no. (%) | .069 | |||
| D/D | 148 (42.9) | 91 (38.6) | 239 (41.1) | |
| D/A | 146 (42.3) | 121 (51.3) | 267 (46.0) | |
| A/A | 51 (14.8) | 24 (10.2) | 75 (12.9) |
Analyses were restricted to patients without missing values in the respective category.
IQR, interquartile range; TOAST, Trial of Org 10172 in Acute Stroke Treatment.
P value from Wilcoxon rank sum test or Fisher exact test.
High-dose statin therapy is defined as a dose equivalent to atorvastatin ≥ 40 mg/d.